Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipid Nanoparticle Delivery of iMDK Induces ATF3-Mediated Apoptosis in Sotorasib-Resistant KRAS Mutant Lung Cancer.

Molecular pharmaceutics - 1 Sept 2025

Liu Bingxin, Fink-Baldauf Iris M, Stuart William D, Jiang Cheng, Naren Anjaparavanda P, Shi Donglu, Guo Minzhe, Whitsett Jeffrey A, Maeda Yutaka

Abstract excerpt

The small molecule iMDK induces apoptosis in H441 papillary lung adenocarcinoma cells that harbor KRASG12V; however, the molecular mechanism by which iMDK induces apoptosis remains unknown. In addition, due to its hydrophobic structure, iMDK is insoluble in water, making iMDK unsuitable for clinical translation. To understand the molecular mechanism, we conducted RNA-seq analysis to identify genes that are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipids

Share to Mice, Nude

Share to Nanoparticles

Share to Proto-Oncogene Proteins p21(ras)

Share to Transcription Factor CHOP

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 40758603
DOI: 10.1021/acs.molpharmaceut.5c00550

Genes

ATF3
KRAS
DDIT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipid Nanoparticle Delivery of iMDK Induces ATF3-Mediated Apoptosis in Sotorasib-Resistant KRAS Mutant Lung Cancer.PMID 40758603Read ↗

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.Semantic proximity Read ↗

Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2.Semantic proximity Read ↗

Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer.Semantic proximity Read ↗

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read ↗

TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4.Semantic proximity Read ↗

Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.Semantic proximity Read ↗

Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer.Semantic proximity Read ↗

Screening of patient-derived organoids identifies mitophagy as a cell-intrinsic vulnerability in colorectal cancer during statin treatmentSemantic proximity Read ↗

Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.Semantic proximity Read ↗

Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis.Semantic proximity Read ↗

CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapySemantic proximity Read ↗

Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.